Elsevier

Annals of Oncology

Volume 29, Supplement 8, October 2018, Page viii729
Annals of Oncology

Late-breaking and deferred publication abstracts
Head and neck cancer, excluding thyroid
LBA8_PR - KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

https://doi.org/10.1093/annonc/mdy424.045Get rights and content
Under an Elsevier user license
open archive

Cited by (0)